Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Brief Summary: The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes).


Options:
A: Arm Label: LY2189265 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Glimepiride | Arm Label: LY2189265 0.75 mg; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Glimepiride | Arm Label: Insulin Glargine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine, Drug: Metformin, Drug: Glimepiride | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Insulin Glargine | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): LY2189265 0.75 mg, LY2189265 1.5 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Insulin Glargine, LY2189265 0.75 mg, LY2189265 1.5 mg | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Insulin Glargine, LY2189265 0.75 mg, LY2189265 1.5 mg
B: Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Pioglitazone | Arm Label: 0.75 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Pioglitazone | Arm Label: Exenatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Exenatide, Drug: Metformin, Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: LY2189265, Drug: Placebo, Drug: Metformin, Drug: Pioglitazone | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Placebo | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Exenatide, Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Exenatide, Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 100 mg q.d. (q.d. = once daily) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Metformin 500 mg b.i.d. | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Metformin 1000 mg b.i.d. | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Drug: Comparator: Metformin 500 mg b.i.d. | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Drug: Comparator: Metformin 1000 mg b.i.d. | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo (Phase A)/Metformin (Phase B) | Arm Label: 7; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d. | Intervention Type: DRUG; Name: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily); Assigned to Arm(s): 4, 5 | Intervention Type: DRUG; Name: Comparator: MK0431 100 mg q.d. (q.d. = once daily); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo (Phase A)/Metformin (Phase B); Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Comparator: Metformin 500 mg b.i.d.; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: Comparator: Metformin 1000 mg b.i.d.; Assigned to Arm(s): 3, 5
D: Arm Label: Saxagliptin 2.5 mg (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 5 mg (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Saxagliptin 10 mg (C); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Placebo matching Metformin, Drug: Metformin | Arm Label: Placebo (D); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching Saxagliptin, Drug: Metformin | Arm Label: Open-Label Treatment Cohort (Direct Enrollees) (E); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 2.5 mg (A) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 10 mg (C) | Intervention Type: DRUG; Name: Placebo matching Saxagliptin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Placebo (D) | Intervention Type: DRUG; Name: Placebo matching Metformin; Assigned to Arm(s): Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Open-Label Treatment Cohort (Direct Enrollees) (E), Placebo (D), Saxagliptin 10 mg (C), Saxagliptin 2.5 mg (A), Saxagliptin 5 mg (B)

Answer: C